Dr. André Dallmann
Dr. André Dallmann works as Scientist for Systems Pharmacology at Bayer, Germany. He completed his PhD in Clinical Pharmacy at the University of Münster, Germany, in 2017. Thereafter, he worked as a postdoctoral researcher at the Pediatric Pharmacology & Pharmacometrics Research Center at the University Children’s Hospital Basel, Switzerland, and in 2018, he joined the department of Clinical Pharmacometrics at Bayer. His research interests focus on in vitro to in vivo extrapolation techniques for oral drug formulations, mechanistic modeling of drug-drug interactions and the exploration of obstetric and neonatal pharmacology through PBPK modeling.
- Liu, X. I., van den Anker, J. N., Burckart, G. J., & Dallmann, A (2021). Evaluation of physiologically-based pharmacokinetic models to predict the absorption of BCS class I drugs in different pediatric age groups. The Journal of Clinical Pharmacology, 1-14. DOI: 10.1002/jcph.1845
- Frechen, S., Solodenko, J., Wendl, T., Dallmann, A., Ince, I., Lehr, T., Lippert, J., & Burghaus, R. (2021). A generic framework for the PBPK platform qualification of PK‐Sim and its application to predicting CYP3A4‐mediated drug‐drug interactions. CPT: Pharmacometrics & Systems Pharmacology, 1-12. DOI: 10.1002/psp4.12636
- Liu, X. I., Momper, J. D., Rakhmanina, N. Y., Green, D. J., Burckart, G. J., Cressey, T. R., Mirochnick, M., Best, B. M., van den Anker, J. N., & Dallmann, A. (2021). Physiologically based pharmacokinetic modeling framework to predict neonatal pharmacokinetics of transplacentally acquired emtricitabine, dolutegravir, and raltegravir. Clinical Pharmacokinetics, 1-15. DOI: 10.1007/s40262-020-00977-w
- Dallmann, A., Pfister, M., van den Anker, J., & Eissing, T. (2018). Physiologically based pharmacokinetic modeling in pregnancy: a systematic review of published models. Clinical Pharmacology & Therapeutics, 104(6), 1110-1124. DOI: 10.1002/cpt.1084